Search Results
Your search for The ,The matches 34708 pages
Showing 30501 - 30550NCCN Presents Rodger Winn Award to Daniel G. Coit, MD
At the 20th Annual Conference of the National Comprehensive Cancer Network (NCCN) held in March 2015 in Hollywood, Florida, NCCN presented Daniel G. Coit, MD, with the Rodger Winn Award. The award, named for NCCN’s “founding father” of the Guidelines Program and the first Editor-in-Chief of the...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2015 Updates
For 2 decades, the NCCN Guidelines® have been recognized as the standard of cancer care in the United States, combining evidence, experience, and choice, so that multidisciplinary cancer treatment teams—including patients—are empowered to make informed decisions about cancer care,” said Robert W....
Expert Point of View: Isaac Brownell, MD, PhD
Isaac Brownell, MD, PhD, Investigator with the Dermatology Branch of the National Cancer Institute, commented on the findings of the Australian ONTRAC trial for The ASCO Post. “This is an interesting finding, and it expands on prior work showing reductions in [ultraviolet]-induced DNA damage and...
Simple Means of Preventing Nonmelanoma Skin Cancer Reported
Two daily doses of nicotinamide, a form of vitamin B3, significantly reduced the occurrence of nonmelanoma skin cancers by 23% in individuals considered at high risk for these lesions in an Australian study. Results of the phase III ONTRAC trial, which will be presented at the 2015 ASCO Annual...
Expert Point of View: Philip L. McCarthy, MD
Another exciting multiple myeloma treatment will be presented at the 2015 ASCO Annual Meeting,” Philip L. McCarthy, MD, Professor of Oncology and Director of the Blood and Marrow Transplant Center at Roswell Park Cancer Institute, Buffalo, New York, commented in an interview with The ASCO Post....
Novel Agent Elotuzumab Added to Lenalidomide/Dexamethasone Extends Progression-Free Survival in Multiple Myeloma
The monoclonal antibody elotuzumab, given with lenalidomide (Revlimid) and dexamethasone, extended progression-free survival by a median of 5 months, compared with lenalidomide/dexamethasone alone, in the eagerly awaited phase III ELOQUENT-2 trial, which will be presented at the 2015 ASCO Annual...
Illumination and Innovation: Transforming Data Into Learning
The ASCO Annual Meeting is our Society’s premier event and without a doubt one that is highly anticipated by the oncology world. The success of the meeting stems from the desire to share with each other our data and the knowledge we have gleaned from those data over the course of the past year. The ...
Expert Point of View: Christopher J. Sweeney, MBBS
These latest results of STAMPEDE lend further support to the early use of chemotherapy in men with advanced prostate cancer. They confirm the CHAARTED trial results reported last year by Christopher J. Sweeney, MBBS, which were practice-changing. Men with newly diagnosed metastatic...
CHAARTED and GETUG-15 Studies
At the 2014 ASCO Annual Meeting, the phase III E3805 (CHAARTED) trial presented at the Plenary Session showed that the addition of docetaxel to standard hormone therapy extended survival by more than 1 year in men with newly diagnosed, hormone-sensitive prostate cancer.1 The survival benefit of...
Docetaxel Combined With Hormone Therapy Extends Survival in Advanced Prostate Cancer
Results from the STAMPEDE trial showed that the addition of docetaxel to standard hormone therapy improved overall survival by a median of 10 months over hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naive prostate cancer.1 The study also showed that zoledronic acid...
About the Contributors
Ronald Piana is an independent writer and reporter with more than 20 years of experience in oncology communications and publishing. In addition to the profiles published in this special supplemental issue of The ASCO Post, Ron has written more than 100 news and feature articles, interviews, and...
In Memoriam: John H. Saiki, MD
John “Jack” Harris Saiki, MD, Professor Emeritus at the University of New Mexico Department of Medicine, Hematology/Oncology Division, lived the history of modern-day oncology with a career spanning 44 years. In the early days of his career, with the support of a grant from the federally funded New ...
In Memoriam: Dorothy ‘Dottie’ Thomas
Dorothy “Dottie” Thomas was wife and research partner to 1990 Nobel laureate E. Donnall Thomas, MD, pioneer of the bone marrow transplant and former Director of the Clinical Research Division at Fred Hutchinson Cancer Research Center. Dr. and Mrs. Thomas formed the core of a team that proved bone...
In Memoriam: Lee W. Wattenberg, MD
One of the early giants in the field of cancer prevention, Lee W. Wattenberg, MD, published in 1966 what would be regarded as a landmark paper in the American Association for Cancer Research (AACR) journal Cancer Research. During his research, he reviewed 36 years of animal studies, looking at the...
In Memoriam: Jesse L. Steinfeld, MD
In 1971, then Surgeon General Jesse L. Steinfeld, MD, took Big Tobacco to task, stating, “Let me suggest that certain purveyors of cigarettes stop making remarks about how some young mothers in childbirth might welcome smaller babies. The mother who smokes is subjecting the unborn child to the...
In Memoriam: John Michael Fitzpatrick, MCh, FRSCI
John Michael Fitzpatrick, MCh, FRSCI, was one of Europe’s most highly regarded medical opinion leaders. He studied medicine at University College Dublin and did his clinical internship at St. Vincent’s Hospital in Dublin. While doing his residency at St. Vincent’s, he decided to become a urologist, ...
In Memoriam: Eddie Reed, MD
Eddie Reed, MD, was a pioneer in the molecular pharmacology of DNA-damaging anticancer agents and the clinical development of paclitaxel for ovarian cancer. He graduated from Yale University School of Medicine in 1979, completed his internship and residency at Stanford University in 1981, and was...
A Tribute to James F. Holland, MD, in Celebration of His 90th Birthday
Far and away the best prize that life has to offer is the chance to work hard at work worth doing. —Theodore Roosevelt Longevity, in and of itself, is not an accomplishment. Luck and good genes are just human lottery tickets. Most people fortunate enough to live long lives have a productive sweet ...
2015 Oncology Meetings
JUNE 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review 2015: Highlights of the Annual MeetingJune 19 • New Haven, Connecticut For more information:...
After a Long and Distinguished Career, Robert C. Young, MD, Shows No Sign of Slowing Down
Robert C. Young, MD, ASCO Past President, longtime leader of Fox Chase Cancer Center, and an internationally recognized expert in lymphoma and ovarian cancer, is a forward-looking doctor who is confident about something not in his future: retirement. “I’ll never quit working; I’m just not wired...
Wyndham H. Wilson, MD, PhD: Shedding Light on the Complexity of Lymphoma Through a Lifetime of Illuminating Research
Dear Dr. Wilson: I am writing to express our family’s deepest and heartfelt appreciation for the lifesaving care you and your team provided for our son, Patrick…. I don’t know how widely it is known that you save lives at the National Cancer Institute—offering hope to people like Patrick, who have...
Andrew C. von Eschenbach, MD, Went From the Front Lines of Cancer Care to a Bird’s-Eye View of the Changing Oncology Landscape
At the end of the day, I’m still a kid from South Philly,” Andrew C. von Eschenbach, MD, former Director of the National Cancer Institute (NCI) and Commissioner of the U.S. Food and Drug Administration (FDA), told The ASCO Post. Dr. von Eschenbach is the product of a closely knit yet culturally...
Global Leader in Drug Development John L. Marshall, MD, Calls for a Smarter War on Cancer
John L. Marshall, MD, a global leader in the research and treatment of gastrointestinal cancers, grew up in Lexington, Kentucky, in a family that put high value on education. As a young boy, science was already on his mind; he enjoyed the explorative nature that chemistry and biology offered....
Nationally Recognized Leader in Myeloid Malignancies, Alan F. List, MD, Has High Hopes for the Future of Oncology
The Tampa Bay area of Florida is a haven for golfers and fishermen looking to unwind under the warm tropical skies. And the clean highways stretching through the scenic west coast of Florida are also a perfect excuse for weekend motorcycle enthusiasts, such as Alan F. List, MD, the President and...
Lymphoma Expert and Industry Leader Sandra J. Horning, MD, Pushes the Frontiers of Drug Development and Oncology Research
Due to childhood health issues, Sandra J. Horning, MD, formed an opinion about doctors at a young age: They were good people who helped other people. By her early teens, Dr. Horning began to ponder a career in medicine, which offered the possibility of blending her love of science with a career...
Pioneer in Combination Chemotherapy, Vincent T. DeVita, Jr, MD, Changed the Face of Modern Oncology
As a young boy growing up in the Bronx, Vincent T. DeVita, Jr, MD, admired the local iceman, a thick-muscled guy known as Nunzi, who used to carry a big block of ice on his shoulder with a set of tongs, and effortlessly slide it into the DeVitas’ icebox. “A friend once asked me what I wanted to be...
Bruce A. Chabner, MD, and His Innovative Pharmacology Research Led to the Development of Practice-Changing Therapies
Numerous challenges and milestones mark the course of an oncology career. Community doctors remember special patients, often speaking about a singular bond that is unique among a profession that deals with life and death daily. Researchers recount long hours of seeming futility and then the...
‘Father of Geriatric Oncology’ Lodovico Balducci, MD, Unearthed a New Understanding of Aging’s Effect on Cancer Treatment
At the 2007 ASCO Annual Meeting, Lodovico Balducci, MD, received the inaugural B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology. Called the “patriarch of geriatric oncology,” Dr. Balducci is widely known in the oncology community for his warm humor and thick Italian...
Carolyn R. ‘Bo’ Aldigé Reflects on 30 Years of Cancer Prevention
In 1985, Carolyn R. “Bo” Aldigé founded the Prevent Cancer Foundation in honor of her father, who had died the previous year of head and neck cancer. She started the Foundation in her kitchen with a typewriter, a sheath of carbon copy paper, and a telephone. “I quickly rented an office because a...
ASCO Announces First-Ever Clinical Trial
ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and Drug...
More Extensive Lymph Node Clearance During Surgery for Esophageal Cancer May Not Improve Survival
A population-based cohort study “indicates that more extensive lymph node clearance during surgery for esophageal cancer may not improve survival,” Maartje van der Schaaf, MD, PhD, of the Karolinska Institutet, Stockholm, and colleagues reported in the Journal of the National Cancer Institute....
First-Line Imatinib With Early Switch to Nilotinib May Be Preferable to First-Line Use of More Potent Agents in CML
Using imatinib to treat chronic-phase chronic myeloid leukemia (CP-CML) first line, with selective switching to nilotinib (Tasigna) “leads to excellent molecular response and survival” and “may be preferable to universal first-line use of more potent agents, considering efficacy, toxicity, and...
Ex Vivo Manipulation of Tumor Microenvironment Improves Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
In a study reported in Clinical Cancer Research, Chacon and colleagues found that ex vivo manipulation of the tumor microenvironment could enhance expansion of tumor-infiltrating lymphocytes for use in adoptive cell therapy. The addition of an agonistic anti–4-1BB antibody during initial tumor...
POLE Proofreading Mutations Predict Better Outcome in Endometrial Cancer
In a study reported in the Journal of the National Cancer Institute, Church and colleagues assessed whether proofreading mutations in POLE (which encodes the DNA polymerase epsilon catalytic subunit) were associated with prognosis in endometrial cancer. Such mutations have been reported in...
Effect of ERG Gene Status on Progression-Free Survival With Abiraterone in Castration-Resistant Prostate Cancer
Gene fusions resulting in androgen receptor–modulated ERG gene overexpression can be found in up to 70% of patients with metastatic castration-resistant prostate cancer. In a study reported in Clinical Cancer Research, Attard and colleagues assessed the effect of ERG rearrangement on outcomes in...
Expect Questions About Preventing Fractures After Stem Cell Transplant
Does the finding that the incidence of fractures is “compellingly higher” after hematopoietic stem cell transplantation mean that physicians counseling patients about transplant should feel compelled to discuss the fracture risks? Huifang Linda Lu, MD, PhD, the corresponding author of the study...
Incidence of Fractures Is ‘Compellingly Higher’ After Hematopoietic Stem Cell Transplantation
The incidence of fractures is “compellingly higher” after receiving hematopoietic stem cell transplantation, according to a retrospective study of patients receiving transplants for treatment of multiple myeloma, other hematologic malignancies, and some solid tumors (mostly breast and ovarian) as...
Gerstner Family Foundation Commits $10 Million to Broad Institute
Broad Institute of MIT and Harvard announced a $10 million gift from the Gerstner Family Foundation, which will expand cancer research at Broad Institute and broaden collaborations with Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center. The research will focus on the...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Cancer Will Always Be Part of My Life
My first experience with cancer was when I was just 9 years old, and a lump the size of an egg popped out on the right side of my neck. A biopsy of the tumor found that it was Hodgkin lymphoma, and I was given huge doses of external-beam radiotherapy applied to my neck, chest, and underarm lymph...
Margaret Foti Recognized as 2015 Honoree of the ‘One Hundred’ by Massachusetts General Hospital Cancer Center
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), was honored for her “dedication and commitment to solving cancer through research” and for her “passionate advocacy for increased federal funding for cancer research and biomedical science,” at Massachusetts...
Meir Wetzler, MD, RPCI Leukemia Chief, Dies at Age 60
Meir Wetzler, MD, Chief of the Leukemia Section at Roswell Park Cancer Institute and University at Buffalo (UB) Professor of Medicine, died on February 23 from injuries sustained during a skiing accident in Colorado. He was 60 years old. Nationally prominent in his field, Dr. Wetzler helped set...
Carol A. Kruse, PhD, Pioneer in Brain Cancer Research and Immunotherapy, Dies at Age 61
Carol A. Kruse, PhD, a University of California, Los Angeles (UCLA) scientist and recognized leader in immunologic therapy for brain cancer, recently passed away in Los Angeles after a 6-month battle with an aggressive form of cancer. She was 61. Dr. Kruse was a UCLA Professor of Neurosurgery and...
Alan C. Sartorelli, PhD, Pioneer in Targeted Chemotherapy and AACR Past President, Dies at Age 83
Alan C. Sartorelli, PhD, Alfred Gilman Professor of Pharmacology at Yale University School of Medicine, Past President of the American Association for Cancer Research (AACR), and a Fellow of the AACR Academy, died on April 30, 2015. A pioneer in cancer chemotherapy, Dr. Sartorelli was one of the...
2015 Oncology Meetings
JUNE The International Society of Ocular Oncology (ISOO) MeetingJune 16-19 • Paris, France For more information: http://www.isoo.org 13th International Conference on Malignant Lymphoma (ICML)June 17-20 • Lugano, Switzerland For more information: www.lymphcon.ch/imcl/index.php2 Yale ASCO® Review...
Martin McMahon, PhD, Joins Research Team at Huntsman Cancer Institute
Martin McMahon, PhD, will join Huntsman Cancer Institute (HCI) at the University of Utah in August 2015 as Professor in the Department of Dermatology and HCI Senior Director of Preclinical Translation. Dr. McMahon is currently the Efim Guzik Distinguished Professor of Cancer Biology at the...
Jonathan L. Finlay, MB, ChB, FRCP, Recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer
During the Wyss Family Symposium, hosted by Nationwide Children’s Hospital May 11–12, Jonathan L. Finlay, MB, ChB, FRCP, Director of Neuro-Oncology at Nationwide Children’s, was announced as the first recipient of the Elizabeth and Richard Germain Endowed Chair in Pediatric Cancer. Dr. Finlay is...
Mount Sinai Receives $8.8 Million Grant to Further Stem Cell Research
An $8.8 million grant from the New York State Stem Cell Science Program (NYSTEM) will accelerate efforts by the Icahn School of Medicine at Mount Sinai to develop new stem cell-based treatments for chemotherapy-resistant blood cancer and other genetic blood disorders. Increasing Stem Cells...
Giving Effective Feedback
Charlene M. Dewey, MD, MEd, FACP, Assistant Dean of Educator Development; Associate Professor of Medical Education and Administration; and Associate Professor of Medicine at Vanderbilt University School of Medicine in Nashville, offers these suggestions for effectively communicating feedback to...
How and When to Give Professional Feedback
Providing students and residents with feedback on their medical performance is a key element in their learning and development and ensures that high standards are met, according to Charlene M. Dewey, MD, MEd, FACP, Assistant Dean of Educator Development; Associate Professor of Medical Education and ...
